The SGLT2i empagliflozin and DPP4i sitagliptin restore insulin sensitivity in HFD/STZ mice by decreasing IRS1 phosphorylation at Tyr632, associated with insulin resistance, and boosting AKT phosphorylation [208]. Here, INS is linked to Insulin resistance.